Modulating nano-bio interface via drug-framework hybridization to activate chemoimmunotherapy against glioma postoperative recurrence

作者：Min Qian, Guangwei Jiang, Senfeng Zhao, Wei Guo, Yi Wang, Yongping Xu, Wenxin Lv, Wenshuai Li, Huifang Nie, Chenteng Lin, Yanhui Qin, Kamiran Aihemaiti, Meng Zhang, Lan Yang, Wenjia Gao, Hongyuan Li, Wei Tao, Rongqin Huang · 发表于：Cell Biomaterials · 年份：2025 · DOI：10.1016/j.celbio.2025.100025 · 被引用次数：9 · 研究领域：Nanoplatforms for cancer theranostics、Nanoparticle-Based Drug Delivery、RNA Interference and Gene Delivery

Regulating the nano-bio interface is crucial for advancing nanomedicine. To address the lack of effective medications for preventing tumor relapse post-surgery, particularly in glioma, we developed a drug-hybridized silica framework (DHSF) through a drug-skeleton hybridization strategy. DHSF refines the nano-biological interface of conventional silica nanomaterials, leading to promising formulations designed to hinder tumor recurrence post-surgery. Integrating doxorubicin (DOX) into the silica framework creates a superior hybrid interface compared with traditional ones. This hybridization facilitates intraoperative drug delivery with enhanced tumor adhesion, hemostatic efficacy, and immune activation via toll-like receptor 4. Moreover, DHSF achieves an extended release of low-dose DOX, thereby downregulating immune checkpoints like PD-L1. The organic-inorganic hybridization also induces tumor microenvironment-stimulated degradation through skeleton relaxation. Consequently, the development of nanosuspensions and photo-stimulative gel for tumor resection demonstrates potential for preventing postoperative recurrence and enhancing chemoimmunotherapy with minimal side effects, particularly in glioma treatment.